

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO : 7,312,237  
 DATED: : December 25, 2007  
 INVENTOR(S) : Francis Y.F. Lee

Page 1 of 2

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page:

Item (54) Title, change "PROLILFERATIVE" to -- PROLIFERATIVE --.

Item (56) References Cited, under Other Publications:

Page 2, column 1, Balog, A. et al. reference, change "(—)." to -- (—)- -- and "23.23m oo," to -- 23/24, pp. --.

The reference should read:

-- Balog, A. et al., "Total Synthesis of (—)-Epothilone A", Angew. Chem. Int. Ed. Engl., vol. 35, No. 23/24, pp. 2801-2803 (1996) --.

Page 2, column 2, third Meng, D. et al., reference, change "Totla" to -- Total -- and "199, No. 43" to -- 119, No. 42 --.

The reference should read:

-- Meng, D. et al., "Total Syntheses of Epothilones A and B", J. Am Chem. Soc., vol. 119, No. 42, pp. 10073-10092 (1997) --.

Page 3, column 2, change "U.S. Appl. No. 60/062,864, Dec. 13, 1996, Nicolaou, K. et al." to -- U.S. Appl. No. 60/032,864, Dec. 13, 1996, Nicolaou, K. et al. --.

In the Specification:

Col. 1, line 4, change "PROLILFERATIVE" to -- PROLIFERATIVE --.

Col. 5, line 24, change "G<sup>3</sup>is" to -- G<sup>3</sup> is --.

Col. 5, line 28, change "G<sup>4</sup>is" to -- G<sup>4</sup> is --.

Col. 9, lines 15 to 19, change

$$\begin{array}{ccc} \text{" G}^8\text{—G}^7\text{"} & & \text{G}^8\text{—G}^7 \\ & \searrow & \searrow \\ & \text{G}^1 & \text{G}^6 \end{array}$$

to

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO : 7,312,237  
 DATED: : December 25, 2007  
 INVENTOR(S) : Francis Y.F. Lee

Page 2 of 2

It is certified that there is an error in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification:

- Col. 9, line 20, change "R<sup>2</sup> is" to -- R<sup>2</sup> is --.
- Col. 13, line 25, change "Gencitabine" to -- Gemcitabine --.
- Col. 15, line 47, change "4thiazolyl" to -- 4-thiazolyl --.
- Col. 17, line 2, change "1-aza" to -- 11-aza --.
- Col. 17, line 43, change "1methyl" to -- 1-methyl --.
- Col. 18, lines 16 to 17, change "11dihydroxy" to -- 11-dihydroxy --.
- Col. 18, line 42, change "10 S\*" to -- 10S\* --.
- Col. 18, line 53, change "17dioxabicyclo" to -- 17-dioxabicyclo --.
- Col. 19, line 1, change "[S" to -- [1S --.
- Col. 19, line 27, change "4thiazolyl" to -- 4-thiazolyl --.
- Col. 25, line 33, change "1R,3R" to -- [1R\*,3R\* --.
- Col. 31, line 27, change "mg/kg/min" to -- mg/kg/inj --.
- Col. 32, line 3, below TABLE 5, insert:  
     -- Tumor Model Characteristics --.
- Col. 32, line 16, change "Fibrosarcorna" to -- Fibrosarcoma --.
- Col. 32, lines 28 to 29, change "(cures/to (tal)" to -- (cures/total) --.
- Col. 32, line 61, change "(>)." to -- (>). --.
- Col. 34, lines 50 to 51, change "(cures/to tal" to -- (cures/total) --.

MAILING ADDRESS OF SENDER:

PATENT NO. 7,312,237

Anastasia P. Winslow  
 Bristol-Myers Squibb Company  
 Patent Department  
 P.O. Box 4000  
 Princeton, NJ 08543-4000  
 (609) 252-6996